According to the Zhitong Finance App, Kaituo Pharmaceutical-B (09939) announced that the Chinese phase II clinical trial for androgenic alopecia in adult women, developed independently by the group and potentially the first of its kind, has reached the main end point. The efficacy of freton is clinically significant, shows significant statistical differences in promoting hair growth, and is safe.

According to the announcement, the phase II clinical trial is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of furatane in treating adult female AGA patients. Professor Zhang Jianzhong, director of dermatology at Peking University People's Hospital, is the main researcher. The primary end point of the clinical trial was the average change in TAHC compared to baseline over 24 weeks of treatment compared to placebo.